Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of "Hold" by Brokerages

Key Points

• Century Therapeutics has an average “Hold” rating from seven analysts: four Buys, two Holds, and one Sell. The average 12-month price target is $4.75, versus a recent share price of $1.88.
• Institutional and hedge-fund investors own 50.2% of the company, with several major investors—including Versant Venture Management, Commodore Capital, and BlackRock—recently establishing positions.
• The biotech reported a quarterly loss of $0.17 per share, missing the consensus estimate of $0.11, while analysts expect a full-year loss of $0.51 per share.

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has received an average rating of "Hold" from the seven analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $4.75.

A number of equities research analysts have recently weighed in on IPSC shares. Wall Street Zen upgraded shares of Century Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, September 12th. Mizuho began coverage on Century Therapeutics in a research report on Wednesday, May 27th. They set an "outperform" rating and a $8.00 price objective for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Century Therapeutics in a report on Thursday, July 2nd.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently modified their holdings of the company. Versant Venture Management LLC acquired a new stake in shares of Century Therapeutics during the first quarter worth about $27,495,000. Commodore Capital LP purchased a new position in shares of Century Therapeutics in the 1st quarter valued at approximately $19,652,000. BlackRock Inc. acquired a new position in shares of Century Therapeutics in the second quarter valued at approximately $19,825,000. Seven Fleet Capital Management LP acquired a new stake in shares of Century Therapeutics during the second quarter worth $10,652,174. Finally, Trails Edge Capital Partners LP acquired a new position in Century Therapeutics in the 2nd quarter valued at $10,130,674. 50.20% of the stock is owned by institutional investors and hedge funds.

Century Therapeutics Stock Up 1.1%

Shares of IPSC opened at $1.88 on Friday. Century Therapeutics has a 52-week low of $0.43 and a 52-week high of $3.04. The company has a market capitalization of $340.41 million, a PE ratio of -2.02 and a beta of 1.59. The stock has a fifty day simple moving average of $2.06 and a two-hundred day simple moving average of $2.22.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.06). As a group, equities analysts anticipate that Century Therapeutics will post -0.51 earnings per share for the current fiscal year.

Century Therapeutics Company Profile

Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer and other serious diseases. The company uses induced pluripotent stem cell (iPSC) technology, gene editing and cell-engineering methods to create potentially off-the-shelf immune cell therapies designed to recognize and eliminate diseased cells.

Its pipeline has included engineered natural killer (NK) cell and T-cell programs targeting blood cancers. Among its leading programs is CNTY-101, an allogeneic CAR NK cell therapy directed at CD19, a target associated with certain B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.